Keep your SARS-CoV-2 testing workflows running at full speed
Reagents for testing and public health labs
One of the many challenges of the public health response to COVID-19 is ensuring that labs have enough high-quality reagents for uninterrupted SARS-CoV-2 testing. With our immense oligonucleotide synthesis capacity and robust reagent supply chain, LGC, Biosearch Technologies™ can remove reagent bottlenecks and keep your SARS-CoV-2 testing workflows running at full speed.
It's not you, it's your oligo. Read how to mitigate the risk of oligo contamination to preserve the integrity of your COVID-19 workflow.
Developing your own kit? What do you require to develop your SARS-CoV-2 assay?Let us know how we can help.
Secure your supply chain needs for scalable SARS-CoV-2 detection
We have mobilised all necessary resources to support global testing requirements. From nucleic acid extraction and purification to critical assay components such as enzymes, master mix, probes and primers, we enable you to respond to COVID-19 rapidly and at scale.
Play video
Why choose Biosearch Technologies to support your COVID-19 detection programs?
Easily order probes and primers by protocol, including a CDC-qualified probe and primer kit
Run your tests with the confidence of knowing that the powerful BHQ™ and BBQ-650™ dyes used in many of the SARS-CoV-2 protocols are coming straight from the company that is the original supplier and inventor
Leverage sensitive and robust qPCR enzymes and master mixes from the trusted partner of the world’s top 10 molecular diagnostic firms
All COVID-19 orders will be prioritised and expedited for detection at scale
“Biosearch Beats the Deadline - Yet another partner went above and beyond: Biosearch Technologies in Novato, in Northern California, produces the Black Hole Quencher dye label used for probe technology in both the five target and H1N1 assays. It increased production at the onset of the pandemic to meet US and international demand for test reagents.”
Excerpt from page 80 of “Lessons from a virus: Public Health Laboratories Respond to the H1N1 Pandemic” Association for Public Health Laboratories
The Biosearch Blog
Get more in-depth insights about COVID-19 and how LGC, Biosearch Technologies is supporting the rapid response to the pandemic from our blog.
-
Wed, Oct 21, 2020 @ 4:00 PM
-
Pressing COVID-19 testing issues of today and the near future
Wed, Aug 26, 2020 @ 2:57 PM
-
Sensitivity and accuracy in COVID-19 testing
Wed, Aug 19, 2020 @ 2:56 PM
-
Scaling up COVID-19 viral testing
Wed, Aug 12, 2020 @ 2:47 PM
-
Enabling a rapid response to COVID-19 by Honeywell and LGC, Biosearch Technologies
Wed, Jul 29, 2020 @ 7:40 PM
Recorded Q&A panel discussion: How to establish COVID-19 diagnostics and keep up with demand
Three leading experts discuss the experiences and challenges they faced when developing, validating and going live with a SARS CoV-2 assay in routine diagnostics as well as the challenges of ramping up test volumes to meet demand while maintaining quality standards. In addition, products specifically designed for SARS-CoV-2 testing, assay validation and QC that can support continued diagnostics at high volumes will be discussed by LGC experts.
View recording
COVID-19 Protocols from WHO and US CDC
WHO interim guidance for laboratory testing: Novel Coronavirus (COVID-19) technical guidance: Laboratory testing for COVID-19 in humans
LGC, Biosearch Technologies is proud to be the original supplier and inventor of the BHQ and BBQ technology used in all of the protocols listed below.
Protocols from across the globe
Probe format used
Order Form
- 2019-Novel Coronavirus (COVID-19) Real-time rRT-PCR Panel Primers and Probes - Centers for Disease Control and Prevention (CDC), USA
BHQ1-labeled probes
- Diagnostic detection of Wuhan coronavirus 2019 by real-time RT-PCR – Charité, Berlin Germany
BBQ-labeled probe
- Detection of 2019 novel coronavirus (COVID-19) in suspected human cases by RT-PCR – Hong Kong University
TAMRA-labeled probe
- China CDC Primers and probes for detection COVID-19
BHQ1- and TAMRA-labeled probes
- PCR and sequencing protocol for COVID-19 - Department of Medical Sciences, Ministry of Public Health, Thailand
BHQ1-labeled probes
- PCR and sequencing protocols for COVID-19- National Institute of Infectious Diseases Japan
BHQ1-labeled probes
- Real-time RT-PCR assays for the detection of SARS-CoV-2 Institut Pasteur, Paris
BHQ1-labeled probes
COVID-19 Resources and downloads
Title
Type
Download
Products to support your workflow
Automation-compatible products for high-quality RNA extraction and purification from a range of clinical samples, including upper respiratory specimens.
-
Bead-based nucleic acid purification chemistry that enables automated high-throughput extraction and purification of high quality RNA.
-
QuickExtract™ DNA Extraction Kit
Used in a fast, efficient, easily automatable one-step RNA extraction method: Sentmanat, et al. One-step RNA extraction for RT-qPCR detection of 2019-nCoV. bioRxiv preprint
High-performance reverse transcriptase (RT) options that can fit into a range of workflows.
-
RapiDxFire 1-step RT-qPCR System
Combines EpiScript RNase H- Reverse Transcriptase and RapiDxFire qPCR 5X Master Mix GF to effectively detect SARS-CoV-2 viral strains with high sensitivity.
-
MMLV High Performance Reverse Transcriptase
Standard reverse transcriptase for temperatures up to 37 °C.
-
RapiDxFire Thermostable Reverse Transcriptase
A novel lyo-compatible, thermostable reverse transcriptase, enabling high temperature cDNA synthesis from complex RNAs
We enable sensitive pathogen detection with our trusted master mix reagents.
-
LavaLAMP RNA Master Mix and LavaLAMP RNA Component Kit
Optimised and flexible kits for and polymerase rapid isothermal amplification and detection of viral RNA, POC (lyo-compatible).
-
Bst DNA Polymerase, Exonuclease Minus
Isothermal DNA polymerase for use in single-step nucleic acid amplification methods such as LAMP.
We offer ready-to-use probe and primer sets that enable confident and scalable SARS-CoV-2 testing.
We safeguard the integrity of your COVID-19 workflows by manufacturing and shipping oligos in a completely separate and geographically distant facility from positive control production.
We’re the inventor and original source of all the quenching technologies that are cited in the protocols published by WHO
You can rely on our secure, vertically integrated supply chain which allows us to manufacture oligos quickly and at scale
Move quickly with a ready-to-use, out-of-the-box solution for high complexity CLIA labs running the CDC EUA protocol.
Pick and choose which COVID-19 signatures work best for your lab with individual RUO probes and primers using sequences as designated by Charité and US CDC protocols:
Request probes of your own design using the BHQ technology we invented:
LGC SeraCare offer a complete Quality Solution for COVID-19 diagnostic assay validation
AccuPlex™ technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient. These materials serve as true, full-process quality solutions that challenge the entire diagnostic workflow, making them the preferred alternative to infectious materials.
Together, the AccuPlex SARS-CoV-2 Verification Panel and AccuPlex SARS-CoV-2 Reference Material Kit offer an ideal solution for clinical laboratories looking for a safe, effective tool to verify and monitor SARS-CoV-2 molecular assay performance. Products contain positive materials directed against the published CDC and WHO consensus sequences and the S gene. Negative materials targeting the human RNase P gene are also included.
“We just went ‘live’ with the SARS-CoV-2 assay…I’ve never brought in and validated an assay in 7 days. The LGC SeraCare reference material works perfectly. I needed something other than the assay’s positive control to create a positive assay result before I felt comfortable releasing the assay for patient testing, and your product did the trick.”
Medical Director, Clinical Chemistry Laboratory prominent Boston Academic Medical Hospital
For testing
Confidently meet surging demand with a large-scale, end-to-end testing solution.
As the need for SARS-CoV-2 testing continues to grow for both diagnostic and screening applications, many organizations are looking to expand or create testing capacity. For existing diagnostic labs, limited supplies of instruments, reagents and laboratory technologists make getting high volumes of testing done in a timely manner challenging.
Biosearch Technologies offers fully automated PCR testing technology that is redefining high-throughput for SARS-CoV-2 detection to 35,000 tests per day on a single system. To further enable mass testing, our ultra-high-throughput PCR testing system is capable of processing up to 150,000 tests per day on a single system.
LEARN MORE
